Categories Earnings, Health Care
Allergan (AGN) Q3 earnings preview: Patent issues, AbbVie deal in focus
After securing shareholders’ approval for the takeover deal with AbbVie (ABBV), Allergan (NYSE: AGN) will be publishing its third-quarter results on November 5 at 7:00 am ET. Market watchers are of the view that earnings will decline 1% annually to $4.22 per share. The estimated revenue is $3.88 billion.
The Irish pharmaceutical firm strengthened its pipeline in recent months by securing key regulatory approvals – including Vraylar for the treatment of bipolar depression and Bimatoprost for glaucoma. Allergan’s flagship product Botox continues to be the main growth driver, supported by other key formulations including Lo Loestrin and Ozurdex.
The positive momentum might help the stock recover from the recent lows. Earnings topped expectations consistently in the trailing quarters, which is expected to be the case this time too.
The ongoing weakness in revenue performance might continue, primarily owing to the recent recall of breast implants that dented customers’ confidence to some extent. Also, the top-line remains under pressure due to competition from the generic market after some of Allergan’s key formulations lost patent recently.
As per initial estimates, the bottom-line will be impacted by a $750 million charge related to the settlement of lawsuits filed by customers against the company’s subsidiary Forest with regard to its Alzheimer’s drugs.
Q2 Performance
In the second quarter, adjusted earnings declined modestly to $4.38 per share on revenues of $4.09 billion, down 1% year-over-year. The results, however, topped expectations.
Bristol-Myers Squibb (BMY) this week reported higher revenues and earnings for the September-quarter, aided by strong sales performance by its key products. Earnings rose 7% annually to $1.17 per share, on revenues of $6 billion.
AbbVie Deal
Earlier this year, Allergan agreed to be acquired by AbbVie for about $63 billion in a cash-and-stock deal. The market will be looking for updates on the progress of the takeover procedures when the management conducts the post-earnings conference call.
Allergan lost significant market share over the last several years and slipped to a six-year low a few months ago. The stock bounced back in the following weeks and gained steadily since then. It is up 23% since then.
Most Popular
Key highlights from Eli Lilly’s (LLY) Q1 2024 earnings results
Eli Lilly and Company (NYSE: LLY) reported first quarter 2024 earnings results today. Worldwide revenue was $8.77 billion, up 26% from the year-ago quarter, driven by increases of 16% in
MCD Earnings: Key quarterly highlights from McDonald’s Q1 2024 financial results
McDonald's Corporation (NYSE: MCD) reported first quarter 2024 earnings results today. Revenues increased 5% year-over-year to $6.1 billion. Revenue growth was 4% in constant currencies. Net income grew 7% to
KO Earnings: All you need to know about Coca-Cola’s Q1 2024 earnings results
The Coca-Cola Company (NYSE: KO) reported its first quarter 2024 earnings results today. Net revenues grew 3% year-over-year to $11.3 billion. Organic revenues grew 11%. Net income attributable to shareowners